Literature DB >> 30873710

Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.

A J Fritz1,2, N E Gillis2,3, D L Gerrard4,5, P D Rodriguez4,5, D Hong6, J T Rose1,2, P N Ghule1,2, E L Bolf2,3, J A Gordon1,2, C E Tye1,2, J R Boyd1,2, K M Tracy1,2, J A Nickerson7, A J van Wijnen8, A N Imbalzano9, J L Heath1,2,10, S E Frietze4,5, S K Zaidi1,2, F E Carr1,2,3, J B Lian1,2, J L Stein1,2, G S Stein1,2.   

Abstract

Cells establish and sustain structural and functional integrity of the genome to support cellular identity and prevent malignant transformation. In this review, we present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization (HCO) that are perturbed in breast cancer onset and progression. Implications for dysfunctions that occur in hormone regulation, cell cycle control, and mitotic bookmarking in breast cancer are considered, with an emphasis on epithelial-to-mesenchymal transition and cancer stem cell activities. The architectural organization of regulatory machinery is addressed within the contexts of translating cancer-compromised genomic organization to advances in breast cancer risk assessment, diagnosis, prognosis, and identification of novel therapeutic targets with high specificity and minimal off target effects.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  RUNX; breast cancer; cancer stem cells; epithelial to mesenchymal transition; higher order chromatin organization; hormone regulation; mitotic bookmarking

Mesh:

Substances:

Year:  2019        PMID: 30873710      PMCID: PMC6549233          DOI: 10.1002/gcc.22731

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  291 in total

Review 1.  Nuclear microenvironments support assembly and organization of the transcriptional regulatory machinery for cell proliferation and differentiation.

Authors:  Gary S Stein; Jane B Lian; Andre J van Wijnen; Janet L Stein; Amjad Javed; Martin Montecino; S Kaleem Zaidi; Daniel Young; Je-Yong Choi; Soraya Gutierrez; Shirwin Pockwinse
Journal:  J Cell Biochem       Date:  2004-02-01       Impact factor: 4.429

Review 2.  Coordinating cell cycle-regulated histone gene expression through assembly and function of the Histone Locus Body.

Authors:  Robert J Duronio; William F Marzluff
Journal:  RNA Biol       Date:  2017-01-06       Impact factor: 4.652

3.  Molecular and Epigenetic Biomarkers in Luminal Androgen Receptor: A Triple Negative Breast Cancer Subtype.

Authors:  Gaëlle Judes; Aslihan Dagdemir; Seher Karsli-Ceppioglu; André Lebert; Marie-Mélanie Dauplat; Khaldoun Rifaï; Marine Daures; Lucas Dubois; Yves-Jean Bignon; Frédérique Penault-Llorca; Dominique Bernard-Gallon
Journal:  OMICS       Date:  2016-06-21

4.  The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements.

Authors:  C K Glass; J M Holloway; O V Devary; M G Rosenfeld
Journal:  Cell       Date:  1988-07-29       Impact factor: 41.582

5.  The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse.

Authors:  Rodrigo Fernandez-Valdivia; Atish Mukherjee; Yan Ying; Jie Li; Marilene Paquet; Francesco J DeMayo; John P Lydon
Journal:  Dev Biol       Date:  2009-01-23       Impact factor: 3.582

6.  Phenotypic transcription factors epigenetically mediate cell growth control.

Authors:  Syed A Ali; Sayyed K Zaidi; Caroline S Dacwag; Nunciada Salma; Daniel W Young; Abdul R Shakoori; Martin A Montecino; Jane B Lian; Andre J van Wijnen; Anthony N Imbalzano; Gary S Stein; Janet L Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-29       Impact factor: 11.205

7.  Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.

Authors:  Pei-Yin Hsu; Hang-Kai Hsu; Xun Lan; Liran Juan; Pearlly S Yan; Jadwiga Labanowska; Nyla Heerema; Tzu-Hung Hsiao; Yu-Chiao Chiu; Yidong Chen; Yunlong Liu; Lang Li; Rong Li; Ian M Thompson; Kenneth P Nephew; Zelton D Sharp; Nameer B Kirma; Victor X Jin; Tim H-M Huang
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

Review 8.  On emerging nuclear order.

Authors:  Indika Rajapakse; Mark Groudine
Journal:  J Cell Biol       Date:  2011-03-07       Impact factor: 10.539

9.  RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.

Authors:  Nyam-Osor Chimge; Gillian H Little; Sanjeev K Baniwal; Helty Adisetiyo; Ying Xie; Tian Zhang; Andie O'Laughlin; Zhi Y Liu; Peaches Ulrich; Anthony Martin; Paulette Mhawech-Fauceglia; Matthew J Ellis; Debu Tripathy; Susan Groshen; Chengyu Liang; Zhe Li; Dustin E Schones; Baruch Frenkel
Journal:  Nat Commun       Date:  2016-02-26       Impact factor: 14.919

10.  A polycomb group protein is retained at specific sites on chromatin in mitosis.

Authors:  Nicole E Follmer; Ajazul H Wani; Nicole J Francis
Journal:  PLoS Genet       Date:  2012-12-20       Impact factor: 5.917

View more
  3 in total

1.  EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.

Authors:  Hao Gong; Yongwen Li; Yin Yuan; Weiting Li; Hongbing Zhang; Zihe Zhang; Ruifeng Shi; Minghui Liu; Chao Liu; Chen Chen; Hongyu Liu; Jun Chen
Journal:  BMC Cancer       Date:  2020-12-04       Impact factor: 4.430

2.  RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells.

Authors:  Andrew J Fritz; Deli Hong; Joseph Boyd; Jason Kost; Kristiaan H Finstaad; Mark P Fitzgerald; Sebastian Hanna; Alqassem H Abuarqoub; Miles Malik; John Bushweller; Coralee Tye; Prachi Ghule; Jonathan Gordon; Seth Frietze; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2020-03-17       Impact factor: 6.513

3.  PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen.

Authors:  Samantha L Tinsley; Brittany L Allen-Petersen
Journal:  NAR Cancer       Date:  2022-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.